Upfront Briefing
Regulators did plenty of price discovery for you: Replimune picked up CRL #2 for RP1 in melanoma, while HHS rewrote the ACIP charter to put more emphasis on vaccine safety.
On the brighter side of the tape, SynOx posted positive Phase 3 topline data for emactuzumab in TGCT — the kind of late-stage de-risking event that can create real strategic optionality even in a niche indication.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,816.9 |
(0.1%) |
(0.4%) |
| Nasdaq 100 |
25,116.3 |
+0.1% |
(0.5%) |
| Russell 2000 |
2,630.6 |
(0.2%) |
+6.0% |
| Healthcare (XLV) |
147.3 |
(1.4%) |
(4.5%) |
| Biotech (XBI) |
129.4 |
(1.8%) |
+6.2% |
| Nasdaq Biotech (NBI) |
5,849.1 |
(1.6%) |
+2.6% |
| Clinical Trials (BBC) |
43.4 |
(2.4%) |
+12.6% |
|
- Friday’s close was choppy rather than outright panic: equities digested hotter March inflation and a sharp jump in gasoline prices while investors also de-risked ahead of U.S.-Iran talks over the weekend.
- Healthcare lagged the broad tape as rising yields and macro uncertainty weighed on longer-duration defensives and growth-sensitive healthcare alike; XLV fell (1.4%) and XBI dropped (1.8%), with biotech underperforming large-cap healthcare.
- Biggest swing: Clinical Trials (BBC) fell (2.4%), the weakest move in the basket, suggesting investors were trimming the highest-beta development-stage exposure into the weekend rather than leaning into risk.
The Big 3
|
1
|
FDA rejects Replimune RP1 in melanoma again with CRL
|
- FDA again rejected Replimune’s RP1 plus nivolumab in advanced melanoma, issuing a second CRL and saying the submission still did not provide adequate evidence of effectiveness from a well-controlled trial.
- Why it matters: This is not just a timing slip. FDA is effectively telling Replimune that single-arm data will not carry this asset across the line, which resets the approval path toward a larger, costlier randomized package. For investors, that means a longer route to revenue, heavier financing risk for a pre-commercial company, and weaker near-term readthrough for oncolytic virus combinations unless cleaner controlled data emerge.
- Source: Endpoints
- More: STAT; BioPharma Dive
|
|
2
|
HHS updates ACIP charter to emphasize vaccine safety
|
- HHS updated the ACIP charter after a legal setback, broadening the committee’s remit around vaccine safety review and reopening the question of who can shape U.S. vaccine recommendations.
- Why it matters: The immediate issue is not vaccine demand today but recommendation-path risk tomorrow. If ACIP becomes less predictable, vaccine developers may face a messier route from approval to clean public-health endorsement, which can affect uptake, contracting, inventory planning and franchise durability—especially in categories where utilization depends heavily on CDC-aligned schedules and committee support.
-
Source:
Endpoints
-
More:
CDC charter; BioPharma Dive
|
| 3 | SynOx posts positive Phase 3 topline for emactuzumab in TGCT |
- SynOx reported positive topline results from the pivotal Phase 3 TANGENT study of emactuzumab in adults with tenosynovial giant cell tumor, a rare but locally aggressive tumor where medical options remain limited for patients not well served by surgery.
- Why it matters: A clean pivotal win matters more than another incremental label extension. TGCT is a specialist market, but positive Phase 3 data put emactuzumab on a potential registrational path in a disease where durable symptom and function improvement can support real commercial value. For investors, this is the kind of late-stage de-risking event that can create partnership, M&A or financing optionality even in a niche indication.
- Source: PR
- More: ClinicalTrials.gov
|
Everything Else that broke
- Roche wins CE mark for Elecsys NfL blood test in MS. — PR
- GSK plans five Phase 3 studies for Hansoh-licensed ADC. — Endpoints
- BioNTech, DualityBio cite Phase 2 efficacy for trastuzumab pamirtecan. — PR
- EMA PRAC highlights include new liver monitoring for Ontozry. — EMA
- FDA asked to revisit mifepristone safety after court action. — BioSpace
- China CRISPR beta thalassemia therapy flags competition risk. — Endpoints
- AbbVie presents Phase 2 ELAHERE data in ovarian cancer at SGO. — PR
- BioVersys cites Nature Communications paper on Alpibectir combo. — PR
- Oral obesity race turns attention to Lilly’s Foundayo launch. — BioSpace
- GSK pulls leucovorin application again after FDA comments. — BioSpace
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
AbbVie licensed ex-China rights from Haisco to multiple novel pain compounds for $30M upfront, up to $715M in development, regulatory and commercial milestones, plus tiered royalties. — PR
VC / Private Financings
- Imbria Pharmaceuticals raised a $57.5M Series B led by Deep Track Capital, joined by AN Ventures, Catalio Capital Management, Cytokinetics, RA Capital Management and SV Health Investors, to fund Phase 2b development in non-obstructive hypertrophic cardiomyopathy. — PR
- Vivatides Therapeutics closed an oversubscribed $54M Series A co-led by Qiming Venture Partners and a leading industry fund, with participation from Highlight Capital, TF Capital and existing investor Apricot Capital, to advance extrahepatic RNA delivery programs into the clinic. — PR
IPOs / Follow-Ons
- Annovis closed an underwritten public offering raising about $10M gross, extending runway through Q2 2027 and funding the company through its Phase 3 Alzheimer’s readout and planned NDA submission. — PR
- Seaport Therapeutics and Hemab both filed for IPOs late Friday, while Kailera remains one of the near-term names expected to test the biotech issuance window. — Endpoints
|
